 Gregory Kinney
Concepts (416)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 59 | 2025 | 1000 | 6.110 |
Why?
| | Coronary Artery Disease | 28 | 2025 | 680 | 1.930 |
Why?
| | Tomography, X-Ray Computed | 43 | 2025 | 2511 | 1.890 |
Why?
| | Smoking | 29 | 2025 | 1502 | 1.830 |
Why?
| | Smokers | 18 | 2025 | 140 | 1.760 |
Why?
| | Diabetes Mellitus, Type 1 | 38 | 2025 | 3630 | 1.600 |
Why?
| | Pulmonary Emphysema | 13 | 2025 | 275 | 1.380 |
Why?
| | Cannabis | 9 | 2024 | 462 | 1.330 |
Why?
| | Forced Expiratory Volume | 26 | 2025 | 508 | 1.240 |
Why?
| | Bronchiectasis | 7 | 2023 | 110 | 1.020 |
Why?
| | Calcinosis | 17 | 2015 | 233 | 0.990 |
Why?
| | Dronabinol | 4 | 2024 | 203 | 0.920 |
Why?
| | Respiratory Function Tests | 11 | 2021 | 581 | 0.850 |
Why?
| | Lung | 23 | 2025 | 3940 | 0.850 |
Why?
| | Hyperlipidemias | 2 | 2023 | 127 | 0.830 |
Why?
| | Spirometry | 16 | 2025 | 257 | 0.830 |
Why?
| | Diabetic Ketoacidosis | 3 | 2022 | 197 | 0.820 |
Why?
| | Cannabinoids | 5 | 2024 | 154 | 0.790 |
Why?
| | Marijuana Smoking | 3 | 2022 | 247 | 0.790 |
Why?
| | Cardiovascular System | 1 | 2023 | 136 | 0.770 |
Why?
| | Disease Progression | 27 | 2025 | 2628 | 0.760 |
Why?
| | Middle Aged | 91 | 2025 | 31177 | 0.750 |
Why?
| | Cardiovascular Diseases | 7 | 2024 | 2008 | 0.720 |
Why?
| | Diabetic Angiopathies | 11 | 2016 | 261 | 0.680 |
Why?
| | Volatilization | 1 | 2019 | 55 | 0.650 |
Why?
| | Nebulizers and Vaporizers | 1 | 2019 | 84 | 0.640 |
Why?
| | Risk Factors | 39 | 2025 | 9801 | 0.620 |
Why?
| | Female | 110 | 2025 | 68829 | 0.620 |
Why?
| | Diabetes Mellitus, Type 2 | 5 | 2023 | 2444 | 0.610 |
Why?
| | Male | 102 | 2025 | 63759 | 0.600 |
Why?
| | Humans | 135 | 2025 | 129847 | 0.600 |
Why?
| | Aged | 49 | 2025 | 22107 | 0.580 |
Why?
| | Coronary Vessels | 7 | 2021 | 239 | 0.550 |
Why?
| | Air Pollution | 1 | 2019 | 218 | 0.530 |
Why?
| | Marijuana Abuse | 1 | 2019 | 233 | 0.520 |
Why?
| | Cohort Studies | 31 | 2025 | 5444 | 0.510 |
Why?
| | Vascular Calcification | 5 | 2019 | 107 | 0.500 |
Why?
| | Risk Assessment | 9 | 2024 | 3269 | 0.490 |
Why?
| | Prospective Studies | 29 | 2025 | 7158 | 0.490 |
Why?
| | Genetic Predisposition to Disease | 11 | 2025 | 2271 | 0.490 |
Why?
| | Arthritis, Rheumatoid | 4 | 2025 | 1098 | 0.490 |
Why?
| | 1-Alkyl-2-acetylglycerophosphocholine Esterase | 2 | 2016 | 23 | 0.480 |
Why?
| | Cigarette Smoking | 3 | 2025 | 91 | 0.470 |
Why?
| | Adult | 56 | 2025 | 35634 | 0.440 |
Why?
| | Genome-Wide Association Study | 9 | 2025 | 1326 | 0.420 |
Why?
| | Vital Capacity | 8 | 2025 | 290 | 0.400 |
Why?
| | Cannabidiol | 2 | 2024 | 108 | 0.380 |
Why?
| | Pulmonary Artery | 5 | 2024 | 1097 | 0.370 |
Why?
| | Longitudinal Studies | 10 | 2024 | 2724 | 0.370 |
Why?
| | Coronary Disease | 7 | 2010 | 385 | 0.360 |
Why?
| | Atherosclerosis | 4 | 2023 | 402 | 0.350 |
Why?
| | Airway Obstruction | 2 | 2024 | 154 | 0.350 |
Why?
| | Emphysema | 2 | 2023 | 109 | 0.340 |
Why?
| | Prevalence | 13 | 2025 | 2564 | 0.340 |
Why?
| | Lung Diseases, Interstitial | 3 | 2025 | 611 | 0.320 |
Why?
| | Marijuana Use | 3 | 2024 | 192 | 0.310 |
Why?
| | Lipoproteins | 3 | 2016 | 172 | 0.300 |
Why?
| | Pectoralis Muscles | 3 | 2021 | 17 | 0.300 |
Why?
| | Depression | 4 | 2022 | 1323 | 0.300 |
Why?
| | Case-Control Studies | 15 | 2025 | 3384 | 0.300 |
Why?
| | Albuminuria | 4 | 2016 | 183 | 0.300 |
Why?
| | Cross-Sectional Studies | 16 | 2025 | 5085 | 0.290 |
Why?
| | Calcium | 7 | 2018 | 1212 | 0.290 |
Why?
| | Severity of Illness Index | 15 | 2023 | 2739 | 0.290 |
Why?
| | Bronchi | 3 | 2022 | 249 | 0.280 |
Why?
| | Metformin | 2 | 2021 | 316 | 0.280 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2024 | 573 | 0.280 |
Why?
| | Young Adult | 15 | 2023 | 12467 | 0.260 |
Why?
| | Body Mass Index | 11 | 2024 | 2274 | 0.260 |
Why?
| | Predictive Value of Tests | 10 | 2019 | 1951 | 0.250 |
Why?
| | Proportional Hazards Models | 6 | 2019 | 1199 | 0.250 |
Why?
| | Biomarkers | 12 | 2024 | 3971 | 0.250 |
Why?
| | Polymorphism, Single Nucleotide | 6 | 2025 | 2062 | 0.250 |
Why?
| | United States | 12 | 2024 | 13913 | 0.240 |
Why?
| | Tandem Mass Spectrometry | 2 | 2019 | 528 | 0.240 |
Why?
| | Hypnotics and Sedatives | 2 | 2019 | 178 | 0.240 |
Why?
| | Quality of Life | 4 | 2021 | 2695 | 0.240 |
Why?
| | Cause of Death | 2 | 2018 | 395 | 0.240 |
Why?
| | Genomic Structural Variation | 1 | 2025 | 12 | 0.240 |
Why?
| | Pulmonary Diffusing Capacity | 3 | 2023 | 74 | 0.230 |
Why?
| | Antidepressive Agents | 3 | 2019 | 229 | 0.230 |
Why?
| | Plaque, Atherosclerotic | 2 | 2023 | 55 | 0.230 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2021 | 198 | 0.230 |
Why?
| | Adrenal Insufficiency | 1 | 2025 | 32 | 0.230 |
Why?
| | Self Administration | 1 | 2025 | 122 | 0.230 |
Why?
| | Aged, 80 and over | 10 | 2024 | 7066 | 0.230 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2025 | 126 | 0.230 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2017 | 321 | 0.220 |
Why?
| | Renal Insufficiency | 2 | 2016 | 149 | 0.220 |
Why?
| | Follow-Up Studies | 11 | 2022 | 4896 | 0.220 |
Why?
| | Birth Weight | 2 | 2024 | 505 | 0.220 |
Why?
| | Vaping | 1 | 2025 | 55 | 0.220 |
Why?
| | C-Peptide | 1 | 2025 | 163 | 0.220 |
Why?
| | Symptom Flare Up | 2 | 2021 | 38 | 0.210 |
Why?
| | Polysomnography | 1 | 2024 | 178 | 0.210 |
Why?
| | Dyspnea | 5 | 2024 | 239 | 0.210 |
Why?
| | Logistic Models | 12 | 2017 | 1989 | 0.210 |
Why?
| | Artificial Intelligence | 2 | 2023 | 245 | 0.200 |
Why?
| | Fibrinogen | 3 | 2014 | 164 | 0.200 |
Why?
| | Tomography, Emission-Computed | 1 | 2022 | 66 | 0.200 |
Why?
| | Multimorbidity | 1 | 2023 | 46 | 0.200 |
Why?
| | Hydrocortisone | 1 | 2025 | 306 | 0.200 |
Why?
| | Propofol | 2 | 2021 | 63 | 0.200 |
Why?
| | Adiponectin | 4 | 2016 | 236 | 0.200 |
Why?
| | Phenotype | 6 | 2025 | 3062 | 0.200 |
Why?
| | Limit of Detection | 2 | 2019 | 83 | 0.200 |
Why?
| | Population Health | 1 | 2023 | 46 | 0.200 |
Why?
| | Umbilical Cord | 2 | 2021 | 83 | 0.190 |
Why?
| | Ketosis | 1 | 2022 | 12 | 0.190 |
Why?
| | Cystatin C | 3 | 2011 | 65 | 0.190 |
Why?
| | Cholesterol | 4 | 2011 | 412 | 0.180 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2023 | 95 | 0.180 |
Why?
| | Molecular Epidemiology | 2 | 2019 | 63 | 0.180 |
Why?
| | Sarcopenia | 1 | 2022 | 74 | 0.180 |
Why?
| | Protective Agents | 1 | 2021 | 39 | 0.180 |
Why?
| | Models, Genetic | 1 | 2024 | 592 | 0.180 |
Why?
| | Hand Strength | 2 | 2022 | 113 | 0.180 |
Why?
| | Self Report | 3 | 2021 | 800 | 0.180 |
Why?
| | Hallucinogens | 1 | 2023 | 102 | 0.180 |
Why?
| | Antirheumatic Agents | 1 | 2023 | 280 | 0.180 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2021 | 89 | 0.170 |
Why?
| | Glucocorticoids | 1 | 2025 | 582 | 0.170 |
Why?
| | Muscular Atrophy | 1 | 2021 | 75 | 0.170 |
Why?
| | C-Reactive Protein | 2 | 2014 | 401 | 0.170 |
Why?
| | Hepatitis C | 1 | 2023 | 244 | 0.170 |
Why?
| | 2-Propanol | 1 | 2019 | 21 | 0.160 |
Why?
| | Delirium | 1 | 2021 | 77 | 0.160 |
Why?
| | Pulmonary Heart Disease | 1 | 2019 | 6 | 0.160 |
Why?
| | B-Lymphocytes | 1 | 2025 | 816 | 0.160 |
Why?
| | Osteoporosis | 1 | 2022 | 231 | 0.160 |
Why?
| | Foam Cells | 1 | 2019 | 15 | 0.160 |
Why?
| | Hyperostosis | 1 | 2019 | 5 | 0.160 |
Why?
| | Genetic Markers | 2 | 2019 | 334 | 0.160 |
Why?
| | Calibration | 1 | 2019 | 140 | 0.160 |
Why?
| | Diabetic Nephropathies | 2 | 2016 | 284 | 0.160 |
Why?
| | Carbon Monoxide | 1 | 2019 | 68 | 0.160 |
Why?
| | Regression Analysis | 6 | 2022 | 998 | 0.160 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2019 | 180 | 0.160 |
Why?
| | Multifactorial Inheritance | 3 | 2025 | 150 | 0.150 |
Why?
| | Sleep | 1 | 2024 | 689 | 0.150 |
Why?
| | Blood Glucose | 6 | 2022 | 2103 | 0.150 |
Why?
| | Anti-Anxiety Agents | 1 | 2019 | 45 | 0.150 |
Why?
| | Adipose Tissue | 2 | 2017 | 594 | 0.150 |
Why?
| | Surface Properties | 1 | 2019 | 400 | 0.150 |
Why?
| | Diabetes Complications | 2 | 2010 | 224 | 0.150 |
Why?
| | Drug Overdose | 1 | 2022 | 326 | 0.150 |
Why?
| | Insulin Resistance | 4 | 2017 | 1168 | 0.140 |
Why?
| | Heart Ventricles | 2 | 2020 | 781 | 0.140 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2019 | 183 | 0.140 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2025 | 634 | 0.140 |
Why?
| | Population Surveillance | 1 | 2021 | 439 | 0.140 |
Why?
| | Organ Size | 4 | 2021 | 456 | 0.140 |
Why?
| | Factor Analysis, Statistical | 1 | 2018 | 284 | 0.140 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 196 | 0.140 |
Why?
| | Polymorphism, Genetic | 3 | 2011 | 636 | 0.140 |
Why?
| | Vascular Remodeling | 1 | 2019 | 192 | 0.140 |
Why?
| | Linear Models | 6 | 2019 | 822 | 0.140 |
Why?
| | Urine | 1 | 2017 | 60 | 0.140 |
Why?
| | Environmental Monitoring | 1 | 2019 | 309 | 0.140 |
Why?
| | HIV Infections | 2 | 2023 | 2730 | 0.140 |
Why?
| | Chronic Disease | 1 | 2023 | 1724 | 0.130 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2017 | 40 | 0.130 |
Why?
| | Lung Diseases | 1 | 2023 | 743 | 0.130 |
Why?
| | Obesity | 4 | 2022 | 2885 | 0.130 |
Why?
| | Bronchitis, Chronic | 1 | 2016 | 19 | 0.130 |
Why?
| | Prenatal Care | 1 | 2019 | 277 | 0.130 |
Why?
| | Blood Pressure | 5 | 2023 | 1736 | 0.130 |
Why?
| | Plasma | 1 | 2017 | 206 | 0.120 |
Why?
| | Anxiety | 2 | 2022 | 976 | 0.120 |
Why?
| | Comorbidity | 5 | 2021 | 1551 | 0.120 |
Why?
| | Aortography | 1 | 2015 | 51 | 0.120 |
Why?
| | Intraoperative Neurophysiological Monitoring | 1 | 2015 | 21 | 0.120 |
Why?
| | Multivariate Analysis | 5 | 2019 | 1501 | 0.120 |
Why?
| | Dexmedetomidine | 1 | 2015 | 44 | 0.120 |
Why?
| | Respiratory System | 1 | 2016 | 156 | 0.120 |
Why?
| | Periodontal Diseases | 1 | 2015 | 61 | 0.120 |
Why?
| | Machine Learning | 1 | 2019 | 441 | 0.120 |
Why?
| | Adiposity | 2 | 2022 | 504 | 0.110 |
Why?
| | Endothelium, Vascular | 1 | 2021 | 902 | 0.110 |
Why?
| | Exercise Tolerance | 3 | 2023 | 273 | 0.110 |
Why?
| | Respiratory Muscles | 1 | 2014 | 32 | 0.110 |
Why?
| | Evoked Potentials, Somatosensory | 2 | 2015 | 33 | 0.110 |
Why?
| | Evoked Potentials | 1 | 2015 | 127 | 0.110 |
Why?
| | Health Status | 2 | 2022 | 758 | 0.110 |
Why?
| | Polycystic Ovary Syndrome | 1 | 2017 | 164 | 0.110 |
Why?
| | Body Composition | 4 | 2021 | 649 | 0.110 |
Why?
| | Subcutaneous Fat | 1 | 2014 | 74 | 0.110 |
Why?
| | Pregnancy Complications | 1 | 2019 | 494 | 0.110 |
Why?
| | Heart | 1 | 2017 | 645 | 0.110 |
Why?
| | Spine | 1 | 2015 | 160 | 0.110 |
Why?
| | Haplotypes | 2 | 2025 | 474 | 0.110 |
Why?
| | Up-Regulation | 1 | 2016 | 836 | 0.100 |
Why?
| | Aorta | 1 | 2015 | 408 | 0.100 |
Why?
| | Sex Distribution | 5 | 2014 | 359 | 0.100 |
Why?
| | Orthopedic Procedures | 1 | 2015 | 209 | 0.100 |
Why?
| | Incidence | 4 | 2024 | 2646 | 0.100 |
Why?
| | Prognosis | 5 | 2024 | 3773 | 0.100 |
Why?
| | Colorado | 6 | 2021 | 4410 | 0.100 |
Why?
| | Surveys and Questionnaires | 8 | 2025 | 5437 | 0.100 |
Why?
| | Time Factors | 7 | 2024 | 6550 | 0.090 |
Why?
| | Imaging, Three-Dimensional | 1 | 2015 | 530 | 0.090 |
Why?
| | Blood Vessels | 1 | 2013 | 187 | 0.090 |
Why?
| | Registries | 1 | 2019 | 1903 | 0.090 |
Why?
| | Triglycerides | 2 | 2011 | 528 | 0.090 |
Why?
| | Haptoglobins | 1 | 2011 | 53 | 0.090 |
Why?
| | Reference Values | 4 | 2023 | 796 | 0.090 |
Why?
| | Occupational Exposure | 1 | 2014 | 302 | 0.090 |
Why?
| | Hypertension, Pulmonary | 1 | 2022 | 1897 | 0.090 |
Why?
| | Genotype | 4 | 2024 | 1829 | 0.090 |
Why?
| | Adolescent | 6 | 2022 | 20451 | 0.090 |
Why?
| | Carotid Intima-Media Thickness | 2 | 2023 | 90 | 0.080 |
Why?
| | Walk Test | 2 | 2021 | 70 | 0.080 |
Why?
| | Patient Education as Topic | 2 | 2005 | 743 | 0.080 |
Why?
| | Alcohol Drinking | 2 | 2009 | 764 | 0.080 |
Why?
| | Diagnostic Techniques, Neurological | 1 | 2009 | 9 | 0.080 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 422 | 0.080 |
Why?
| | Coma | 1 | 2009 | 32 | 0.080 |
Why?
| | Retrospective Studies | 8 | 2021 | 14553 | 0.080 |
Why?
| | Pediatric Obesity | 1 | 2017 | 573 | 0.080 |
Why?
| | Pregnancy | 4 | 2024 | 6423 | 0.080 |
Why?
| | Facial Nerve | 1 | 2009 | 34 | 0.080 |
Why?
| | Aortic Diseases | 1 | 2010 | 114 | 0.080 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2009 | 33 | 0.080 |
Why?
| | Lymphatic Abnormalities | 1 | 2009 | 19 | 0.080 |
Why?
| | Uric Acid | 1 | 2010 | 161 | 0.080 |
Why?
| | Monitoring, Intraoperative | 1 | 2009 | 51 | 0.080 |
Why?
| | Respiratory Physiological Phenomena | 2 | 2022 | 30 | 0.080 |
Why?
| | Sensitivity and Specificity | 3 | 2022 | 1847 | 0.080 |
Why?
| | Hypertension | 5 | 2015 | 1242 | 0.080 |
Why?
| | Reproducibility of Results | 5 | 2017 | 3089 | 0.080 |
Why?
| | Diet, Ketogenic | 1 | 2009 | 37 | 0.080 |
Why?
| | Airway Remodeling | 2 | 2021 | 64 | 0.080 |
Why?
| | Odds Ratio | 4 | 2014 | 1022 | 0.080 |
Why?
| | Asymptomatic Diseases | 2 | 2021 | 84 | 0.080 |
Why?
| | Anesthesia, Intravenous | 2 | 2021 | 15 | 0.080 |
Why?
| | Kidney | 1 | 2016 | 1383 | 0.070 |
Why?
| | Proteinuria | 1 | 2009 | 91 | 0.070 |
Why?
| | Aorta, Thoracic | 1 | 2010 | 263 | 0.070 |
Why?
| | Reproductive History | 1 | 2008 | 18 | 0.070 |
Why?
| | Sex Factors | 4 | 2020 | 1973 | 0.070 |
Why?
| | Coronary Angiography | 2 | 2014 | 306 | 0.070 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.070 |
Why?
| | Face | 1 | 2009 | 165 | 0.070 |
Why?
| | Radiography | 3 | 2016 | 800 | 0.070 |
Why?
| | Cystatins | 1 | 2007 | 7 | 0.070 |
Why?
| | Asthma | 1 | 2021 | 2225 | 0.070 |
Why?
| | Age of Onset | 2 | 2025 | 494 | 0.070 |
Why?
| | Inflammation | 2 | 2021 | 2748 | 0.070 |
Why?
| | Life Style | 1 | 2009 | 462 | 0.070 |
Why?
| | Dietary Fats | 1 | 2009 | 303 | 0.070 |
Why?
| | Heart Rate | 1 | 2010 | 804 | 0.070 |
Why?
| | Mortality | 2 | 2019 | 308 | 0.070 |
Why?
| | Kidney Diseases | 1 | 2010 | 382 | 0.070 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 82 | 0.060 |
Why?
| | Apolipoproteins A | 1 | 2006 | 19 | 0.060 |
Why?
| | Child, Preschool | 4 | 2024 | 10522 | 0.060 |
Why?
| | Apolipoproteins C | 1 | 2006 | 6 | 0.060 |
Why?
| | Contraception | 1 | 2008 | 153 | 0.060 |
Why?
| | Propensity Score | 2 | 2019 | 266 | 0.060 |
Why?
| | Cluster Analysis | 2 | 2019 | 483 | 0.060 |
Why?
| | Receptors, Interleukin-2 | 1 | 2005 | 64 | 0.060 |
Why?
| | Internationality | 2 | 2017 | 150 | 0.060 |
Why?
| | Receptors, IgG | 1 | 2005 | 73 | 0.060 |
Why?
| | Chi-Square Distribution | 3 | 2010 | 515 | 0.060 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2010 | 430 | 0.060 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2025 | 79 | 0.060 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2025 | 50 | 0.060 |
Why?
| | Abdominal Wall | 1 | 2004 | 23 | 0.060 |
Why?
| | Pandemics | 2 | 2024 | 1500 | 0.060 |
Why?
| | Antihypertensive Agents | 2 | 2007 | 485 | 0.060 |
Why?
| | Drug Repositioning | 1 | 2024 | 26 | 0.060 |
Why?
| | Protein Interaction Maps | 1 | 2024 | 42 | 0.060 |
Why?
| | Apolipoprotein C-III | 2 | 2019 | 13 | 0.060 |
Why?
| | Whole Genome Sequencing | 1 | 2025 | 128 | 0.060 |
Why?
| | United Kingdom | 1 | 2024 | 258 | 0.050 |
Why?
| | HLA Antigens | 1 | 2025 | 235 | 0.050 |
Why?
| | Glomerular Filtration Rate | 3 | 2016 | 711 | 0.050 |
Why?
| | Glucose Clamp Technique | 2 | 2017 | 194 | 0.050 |
Why?
| | Cholesterol, LDL | 1 | 2005 | 358 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 373 | 0.050 |
Why?
| | Antigens, CD | 1 | 2005 | 487 | 0.050 |
Why?
| | Insulin | 3 | 2022 | 2330 | 0.050 |
Why?
| | Nutrition Surveys | 1 | 2024 | 260 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2023 | 157 | 0.050 |
Why?
| | Blood Platelets | 1 | 2005 | 386 | 0.050 |
Why?
| | Morbidity | 1 | 2022 | 302 | 0.050 |
Why?
| | Radiography, Thoracic | 2 | 2014 | 165 | 0.050 |
Why?
| | Muscles | 1 | 2022 | 320 | 0.050 |
Why?
| | Survival Analysis | 2 | 2017 | 1271 | 0.050 |
Why?
| | Lung Volume Measurements | 1 | 2021 | 45 | 0.050 |
Why?
| | Biological Variation, Population | 1 | 2021 | 21 | 0.050 |
Why?
| | Hepacivirus | 1 | 2023 | 242 | 0.040 |
Why?
| | Reaction Time | 2 | 2015 | 411 | 0.040 |
Why?
| | Protective Factors | 1 | 2021 | 91 | 0.040 |
Why?
| | Plethysmography | 1 | 2021 | 106 | 0.040 |
Why?
| | Breast Feeding | 1 | 2024 | 424 | 0.040 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2021 | 36 | 0.040 |
Why?
| | Hospitals, Urban | 1 | 2021 | 135 | 0.040 |
Why?
| | Anesthesia, General | 1 | 2021 | 60 | 0.040 |
Why?
| | Substance Abuse Detection | 1 | 2021 | 79 | 0.040 |
Why?
| | Diabetes Mellitus | 1 | 2009 | 1003 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2022 | 374 | 0.040 |
Why?
| | Models, Statistical | 1 | 2024 | 624 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 459 | 0.040 |
Why?
| | Hospitals, Pediatric | 2 | 2017 | 517 | 0.040 |
Why?
| | Homosexuality, Male | 1 | 2021 | 176 | 0.040 |
Why?
| | Oligodeoxyribonucleotides, Antisense | 1 | 2019 | 8 | 0.040 |
Why?
| | Computer Simulation | 1 | 2024 | 941 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2021 | 10241 | 0.040 |
Why?
| | Lipids | 2 | 2017 | 628 | 0.040 |
Why?
| | rab4 GTP-Binding Proteins | 1 | 2019 | 9 | 0.040 |
Why?
| | Cytochrome P-450 CYP2B6 | 1 | 2019 | 9 | 0.040 |
Why?
| | Cytochrome P450 Family 2 | 1 | 2019 | 12 | 0.040 |
Why?
| | Analysis of Variance | 2 | 2014 | 1291 | 0.040 |
Why?
| | Bronchodilator Agents | 1 | 2021 | 245 | 0.040 |
Why?
| | RNA, Viral | 1 | 2023 | 620 | 0.040 |
Why?
| | Proof of Concept Study | 1 | 2019 | 69 | 0.040 |
Why?
| | Multidetector Computed Tomography | 1 | 2019 | 33 | 0.040 |
Why?
| | Aryl Hydrocarbon Hydroxylases | 1 | 2019 | 48 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2021 | 673 | 0.040 |
Why?
| | Genetic Variation | 1 | 2024 | 937 | 0.040 |
Why?
| | Bone Density | 1 | 2022 | 463 | 0.040 |
Why?
| | Genomics | 1 | 2023 | 716 | 0.040 |
Why?
| | Europe | 1 | 2019 | 363 | 0.040 |
Why?
| | Electroencephalography | 1 | 2021 | 409 | 0.040 |
Why?
| | Exercise | 1 | 2009 | 1934 | 0.040 |
Why?
| | Systems Biology | 1 | 2018 | 60 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1042 | 0.040 |
Why?
| | Atmospheric Pressure | 1 | 2017 | 23 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2024 | 1686 | 0.040 |
Why?
| | Electrocardiography | 2 | 2010 | 613 | 0.030 |
Why?
| | Electric Impedance | 1 | 2017 | 102 | 0.030 |
Why?
| | Maternal Health Services | 1 | 2019 | 92 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2021 | 532 | 0.030 |
Why?
| | Total Lung Capacity | 1 | 2016 | 33 | 0.030 |
Why?
| | Diagnostic Imaging | 1 | 2019 | 326 | 0.030 |
Why?
| | Michigan | 1 | 2017 | 104 | 0.030 |
Why?
| | Glucose | 1 | 2022 | 1003 | 0.030 |
Why?
| | Bronchial Arteries | 1 | 2016 | 12 | 0.030 |
Why?
| | Causality | 1 | 2017 | 117 | 0.030 |
Why?
| | RNA | 1 | 2023 | 877 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 851 | 0.030 |
Why?
| | Area Under Curve | 1 | 2016 | 306 | 0.030 |
Why?
| | Urban Population | 1 | 2019 | 443 | 0.030 |
Why?
| | Statistics as Topic | 1 | 2016 | 306 | 0.030 |
Why?
| | Evoked Potentials, Visual | 1 | 2015 | 35 | 0.030 |
Why?
| | Evoked Potentials, Motor | 1 | 2015 | 40 | 0.030 |
Why?
| | Automation | 1 | 2015 | 81 | 0.030 |
Why?
| | Cough | 1 | 2016 | 117 | 0.030 |
Why?
| | Anesthetics, Intravenous | 1 | 2015 | 46 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2017 | 585 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1125 | 0.030 |
Why?
| | Infant | 2 | 2024 | 9018 | 0.030 |
Why?
| | Muscle Strength | 1 | 2018 | 304 | 0.030 |
Why?
| | ROC Curve | 1 | 2016 | 504 | 0.030 |
Why?
| | Physical Endurance | 1 | 2016 | 264 | 0.030 |
Why?
| | Sex Characteristics | 2 | 2014 | 735 | 0.030 |
Why?
| | Stroke | 1 | 2003 | 1072 | 0.030 |
Why?
| | Gastroesophageal Reflux | 1 | 2017 | 232 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2017 | 505 | 0.030 |
Why?
| | Piperidines | 1 | 2015 | 200 | 0.030 |
Why?
| | Dyslipidemias | 1 | 2015 | 177 | 0.030 |
Why?
| | Mice | 2 | 2021 | 16983 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2024 | 5772 | 0.030 |
Why?
| | Hypercholesterolemia | 1 | 2014 | 102 | 0.030 |
Why?
| | Angiography | 1 | 2013 | 197 | 0.020 |
Why?
| | Quality Improvement | 1 | 2021 | 1112 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2019 | 2888 | 0.020 |
Why?
| | Vascular Stiffness | 1 | 2017 | 467 | 0.020 |
Why?
| | Child | 2 | 2025 | 20962 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 338 | 0.020 |
Why?
| | Exercise Test | 1 | 2014 | 614 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5468 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2015 | 1877 | 0.020 |
Why?
| | Gene Frequency | 1 | 2011 | 500 | 0.020 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2016 | 567 | 0.020 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2010 | 99 | 0.020 |
Why?
| | Median Nerve | 1 | 2009 | 23 | 0.020 |
Why?
| | Facial Paralysis | 1 | 2009 | 17 | 0.020 |
Why?
| | Intra-Abdominal Fat | 1 | 2010 | 88 | 0.020 |
Why?
| | Artifacts | 1 | 2009 | 127 | 0.020 |
Why?
| | Observer Variation | 1 | 2009 | 314 | 0.020 |
Why?
| | Personality Inventory | 1 | 2009 | 139 | 0.020 |
Why?
| | Animals | 2 | 2021 | 35409 | 0.020 |
Why?
| | Age Factors | 2 | 2007 | 3161 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 426 | 0.020 |
Why?
| | Diabetic Neuropathies | 1 | 2009 | 96 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1617 | 0.020 |
Why?
| | Health Surveys | 1 | 2009 | 495 | 0.020 |
Why?
| | Angiotensins | 1 | 2007 | 9 | 0.020 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 22 | 0.020 |
Why?
| | Electromyography | 1 | 2009 | 381 | 0.020 |
Why?
| | Preoperative Care | 1 | 2009 | 337 | 0.020 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 53 | 0.020 |
Why?
| | Contraceptive Agents, Female | 1 | 2008 | 78 | 0.020 |
Why?
| | Diabetic Retinopathy | 1 | 2009 | 179 | 0.020 |
Why?
| | Patient Selection | 1 | 2010 | 660 | 0.020 |
Why?
| | Self Care | 1 | 2009 | 368 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2006 | 284 | 0.010 |
Why?
| | Waist-Hip Ratio | 1 | 2004 | 35 | 0.010 |
Why?
| | Platelet Aggregation | 1 | 2005 | 97 | 0.010 |
Why?
| | Hospitalization | 1 | 2014 | 2079 | 0.010 |
Why?
| | Radiography, Abdominal | 1 | 2004 | 46 | 0.010 |
Why?
| | Age Distribution | 1 | 2005 | 372 | 0.010 |
Why?
| | Anthropometry | 1 | 2004 | 204 | 0.010 |
Why?
| | Feeding Behavior | 1 | 2009 | 626 | 0.010 |
Why?
| | Alleles | 1 | 2006 | 843 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2005 | 1160 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2006 | 1213 | 0.010 |
Why?
| | Neoplasms | 1 | 2016 | 2454 | 0.010 |
Why?
| | Risk | 1 | 2003 | 860 | 0.010 |
Why?
| | Hyperglycemia | 1 | 2003 | 327 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2006 | 1264 | 0.010 |
Why?
| | DNA | 1 | 2006 | 1406 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2009 | 2481 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2005 | 1221 | 0.010 |
Why?
|
|
Kinney's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|